A Phase 1 Study of MLN9708 in Japanese Patients with Relapsed and/or Refractory Multiple Myeloma

Trial Profile

A Phase 1 Study of MLN9708 in Japanese Patients with Relapsed and/or Refractory Multiple Myeloma

Completed
Phase of Trial: Phase I

Latest Information Update: 27 Jun 2017

At a glance

  • Drugs Ixazomib (Primary) ; Dexamethasone; Lenalidomide
  • Indications Multiple myeloma
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Takeda
  • Most Recent Events

    • 01 Apr 2017 Results published in the International Journal of Hematology
    • 01 Apr 2017 Status changed from recruiting to completed according to results published in the International Journal of Hematology.
    • 07 Jun 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top